**Participants with a neurodegenerative condition in the NDIS**

**Data at 31 March 2021**

**National Disability Insurance Agency**

## Table of Contents

[Table of Contents 2](#_Toc73974639)

[Slide 1: Participants with a neurodegenerative condition in the NDIS 6](#_Toc73974640)

[Slide 2: Outline 6](#_Toc73974641)

[Slide 3: Introduction 6](#_Toc73974642)

[Slide 4: Definitions – Disability types classification 7](#_Toc73974643)

[Slide 5: Definitions – Disability types description 7](#_Toc73974644)

[Slide 6: Definitions – Disability types description (continued) 8](#_Toc73974645)

[Slide 7: Description – Key terms 9](#_Toc73974646)

[Slide 8: Definitions – Key measures 9](#_Toc73974647)

[Slide 9: Part 1: Participants 10](#_Toc73974648)

[Slide 10: Summary 10](#_Toc73974649)

[Slide 11: Participation rates by State/Territory 11](#_Toc73974650)

[Slide 12: Participation rates by State/Territory (continued) 11](#_Toc73974651)

[Slide 13: Participation rates by age group 12](#_Toc73974652)

[Slide 14: Participation rates by age group (continued) 12](#_Toc73974653)

[Slide 15: Participants over time 12](#_Toc73974654)

[Slide 16: Participants over time (continued) 13](#_Toc73974655)

[Slide 17: Participants by age group 13](#_Toc73974656)

[Slide 18: Participants by age group (continued) 13](#_Toc73974657)

[Slide 19: Participants by Indigenous and CALD status 14](#_Toc73974658)

[Slide 20: Participants by Existing/New status, by level of function 14](#_Toc73974659)

[Slide 21: Participants by gender and remoteness 15](#_Toc73974660)

[Slide 22: Part 2: Participant experience 15](#_Toc73974661)

[Slide 23: Summary 15](#_Toc73974662)

[Slide 24: Access decisions and PSG Access metrics 16](#_Toc73974663)

[Slide 25: Access decisions by age group 17](#_Toc73974664)

[Slide 26: Access decisions by age group (continued) 17](#_Toc73974665)

[Slide 27: Participant Service Guarantee: Planning metrics 17](#_Toc73974666)

[Slide 28: Participant Service Guarantee: Planning metrics (continued) 18](#_Toc73974667)

[Slide 29: Participant Service Guarantee: Participant Requested Review metrics 18](#_Toc73974668)

[Slide 30: Participant Service Guarantee: Participant Requested Review metrics (continued) 19](#_Toc73974669)

[Slide 31: Participant Service Guarantee: Review of Reviewable Decision metrics 19](#_Toc73974670)

[Slide 32: Participant Service Guarantee: Review of Reviewable Decision metrics (continued) 19](#_Toc73974671)

[Slide 33: Participants by plan management type 20](#_Toc73974672)

[Slide 34: Participants by plan management type (continued) 20](#_Toc73974673)

[Slide 35: Plan duration 20](#_Toc73974674)

[Slide 36: Assistive technology and support coordination in plans 21](#_Toc73974675)

[Slide 37: Scheme exit rates over time 21](#_Toc73974676)

[Slide 38: Scheme exit rates over time (continued) 21](#_Toc73974677)

[Slide 39: Complaint rates 22](#_Toc73974678)

[Slide 40: Complaint rates (continued) 22](#_Toc73974679)

[Slide 41: Part 3: Committed supports, payments and utilisation 22](#_Toc73974680)

[Slide 42: Summary 23](#_Toc73974681)

[Slide 43: Trend in committed supports 24](#_Toc73974682)

[Slide 44: Trend in committed supports (continued) 24](#_Toc73974683)

[Slide 45: Committed supports by age group 24](#_Toc73974684)

[Slide 46: Committed supports by age group (continued) 25](#_Toc73974685)

[Slide 47: Committed supports by SIL status 25](#_Toc73974686)

[Slide 48: Distribution of committed supports 25](#_Toc73974687)

[Slide 49: Distribution of committed supports (continued) 26](#_Toc73974688)

[Slide 50: Types of committed supports 26](#_Toc73974689)

[Slide 51: Types of committed supports (continued) 26](#_Toc73974690)

[Slide 52: Changes in committed supports 26](#_Toc73974691)

[Slide 53: Changes in committed supports (continued) 27](#_Toc73974692)

[Slide 54: Average annualised payments 27](#_Toc73974693)

[Slide 55: Average annualised payments (continued) 27](#_Toc73974694)

[Slide 56: Utilisation by time in the Scheme 28](#_Toc73974695)

[Slide 57: Utilisation by time in the Scheme (continued) 28](#_Toc73974696)

[Slide 58: Utilisation by age group 28](#_Toc73974697)

[Slide 59: Utilisation by age group (continued) 29](#_Toc73974698)

[Slide 60: Utilisation by SIL status 29](#_Toc73974699)

[Slide 61: Part 4: Participant goals, outcomes and satisfaction 29](#_Toc73974700)

[Slide 62: Participant goals, outcomes and satisfaction - technical notes 30](#_Toc73974701)

[Slide 63: Summary 30](#_Toc73974702)

[Slide 64: Key findings 32](#_Toc73974703)

[Slide 65: Participant goals 33](#_Toc73974704)

[Slide 66: Participant goals (continued) 33](#_Toc73974705)

[Slide 67: Participant baseline outcomes – Muscular dystrophy 34](#_Toc73974706)

[Slide 68: Participant baseline outcomes – Huntington’s disease 35](#_Toc73974707)

[Slide 69: Participant baseline outcomes – Motor neurone disease 35](#_Toc73974708)

[Slide 70: Participant baseline outcomes – Multiple sclerosis 36](#_Toc73974709)

[Slide 71: Participant baseline outcomes – Parkinson’s disease 37](#_Toc73974710)

[Slide 72: Family/carer baseline outcomes – Muscular dystrophy 37](#_Toc73974711)

[Slide 73: Family/carer baseline outcomes – Huntington’s disease 38](#_Toc73974712)

[Slide 74: Family/carer baseline outcomes – Motor neurone disease 38](#_Toc73974713)

[Slide 75: Family/carer baseline outcomes – Multiple sclerosis 39](#_Toc73974714)

[Slide 76: Family/carer baseline outcomes – Parkinson’s disease 40](#_Toc73974715)

[Slide 77: Participant longitudinal outcomes – Muscular dystrophy 40](#_Toc73974716)

[Slide 78: Participant longitudinal outcomes – Huntington’s disease 41](#_Toc73974717)

[Slide 79: Participant longitudinal outcomes – Motor neurone disease 42](#_Toc73974718)

[Slide 80: Participant longitudinal outcomes – Multiple sclerosis 42](#_Toc73974719)

[Slide 81: Participant longitudinal outcomes – Parkinson’s disease 43](#_Toc73974720)

[Slide 82: Family/Carer longitudinal outcomes – Muscular dystrophy 43](#_Toc73974721)

[Slide 83: Family/Carer longitudinal outcomes – Huntington’s disease 44](#_Toc73974722)

[Slide 84: Family/Carer longitudinal outcomes – Motor neurone disease 44](#_Toc73974723)

[Slide 85: Family/Carer longitudinal outcomes – Multiple sclerosis 44](#_Toc73974724)

[Slide 86: Family/Carer longitudinal outcomes – Parkinson’s disease 45](#_Toc73974725)

[Slide 87: Has the NDIS Helped participants – Muscular dystrophy (participants from starting school to age 14) 45](#_Toc73974726)

[Slide 88: Has the NDIS Helped participants – Muscular dystrophy (participants aged 15 and over) 45](#_Toc73974727)

[Slide 89: Has the NDIS Helped participants – Huntington’s disease 46](#_Toc73974728)

[Slide 90: Has the NDIS Helped participants – Motor neurone disease 47](#_Toc73974729)

[Slide 91: Has the NDIS Helped participants – Multiple sclerosis 48](#_Toc73974730)

[Slide 92: Has the NDIS Helped participants – Parkinson’s disease 48](#_Toc73974731)

[Slide 93: Has the NDIS Helped families/carers - Muscular dystrophy (families and carers of participants aged 0 to 14) 49](#_Toc73974732)

[Slide 94: Has the NDIS Helped families/carers - Muscular dystrophy (families and carers of participants aged 15 and over) 50](#_Toc73974733)

[Slide 95: Has the NDIS Helped families/carers – Multiple sclerosis 50](#_Toc73974734)

[Slide 96: Has the NDIS Helped families/carers – Parkinson’s disease 51](#_Toc73974735)

[Slide 97: Participant Satisfaction - the Planning stage 51](#_Toc73974736)

[Slide 98: Participant Satisfaction - the Review stage 52](#_Toc73974737)

## Slide 1: Participants with a neurodegenerative condition in the NDIS

This slide is the cover page for the report.

Data at 31 March 2021

## Slide 2: Outline

This slide outlines the structure of the report by section.

* Introduction and definitions:

This section describes five neurodegenerative conditions considered in this report: Muscular dystrophy, Huntington's disease, Motor neurone disease, Multiple sclerosis and Parkinson's disease. Various key terms used in this report are explained as well as measures such as committed supports, payments and complaint rates.

* Participants

This section presents information on the profile of participants with a neurodegenerative condition across various participant characteristics such as age, Indigenous status and gender. Scheme participation rates are also presented.

* Participant experience

This section includes various measures of the Scheme as experienced by participants, including eligibility rates, Participant Service Guarantee (PSG) metrics, as well as rates of exits and complaints.

* Committed supports, payments and utilisation

This section presents average annualised committed supports and utilisation of supports by participant characteristics such as age and Supported Independent Living (SIL) status, as well as the distribution and types of committed supports in participant plans. Average annualised payments by financial year are also included.

* Participant goals, outcomes and satisfaction

This section presents participant goals, followed by outcomes for participants and their families and carers. Outcomes results include those recorded at Scheme entry (baseline) and also longitudinal survey responses. The report concludes with results from the Participant Satisfaction Survey (PSS).

## Slide 3: Introduction

This slide introduces the purpose of this report.

The National Disability Insurance Scheme (NDIS) provides reasonable and necessary funding to people with a permanent and significant disability to access the supports and services they need to assist with achieving their goals and outcomes.

The purpose of this report is to present on the experience of NDIS participants with one of the following neurodegenerative conditions, using data at **31 March 2021:**

* Muscular dystrophy
* Huntington's disease
* Motor neurone disease
* Multiple sclerosis
* Parkinson's disease

## Slide 4: Definitions – Disability types classification

This slide defines the disability types of interest by ICD-10 diagnosis codes.

Disability types used by the NDIS are based on ICD-10 (International Statistical Classification of Diseases and Related Health Problems) codes which are relevant to the Scheme.

The ICD is a classification system which is a global standard for health data, clinical documentation and statistical aggregation.

The diagnosis codes associated with the disability types in this report as are follows:

* Muscular dystrophy: G71.0 - Muscular dystrophy
* Huntington's disease: G10 - Huntington's disease
* Motor neurone disease: G12.2 - Motor neurone disease (also called amyotrophic lateral sclerosis)
* Multiple sclerosis: G35 - Multiple sclerosis
* Parkinson’s disease: G20 - Parkinson's disease

## Slide 5: Definitions – Disability types description

This slide provides a brief description of each of the five neurodegenerative conditions considered in this report.

Neurodegenerative conditions are disorders that predominantly affect cells in the brain called neurons. Neurons are specialised cells that allow the brain to communicate with the rest of the body. When neurons become damaged or die, there is a loss of brain activity leading to problems with movement or mental functioning.\*

While there is a diverse range of neurodegenerative conditions, this report considers the following five common types. The description for each condition is sourced from The Brain Foundation Australia.\*\*

* Muscular dystrophy

This refers to a group of genetic (inherited) conditions that cause progressive deterioration of the body’s muscles, with increasing weakness and disability.

The main different types are Duchenne muscular dystrophy, Becker-type muscular dystrophy, Myotonic dystrophy, Limb-girdle muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Most forms of muscular dystrophy are chronic and progressive and persist throughout life. Early death may result from severe involvement of respiratory or cardiac muscles. Currently, there is no cure for Muscular dystrophy and no way to stop its progression.

* Huntington's disease:

This is an inherited disease of the brain that affects the nervous system. The classic signs of the condition include emotional, cognitive and motor disturbances. Men and women are at equal risk of inheriting the disease, and it can appear at any age though manifestations typically become evident during the fourth or fifth decades of life. It is likely that the earlier the onset the faster the disease seems to progress.

This is a progressive condition, and the duration of the illness ranges from 10 to 30 years. Symptoms are not usually presented by the person. The person often has poor insight into the changes occurring which vary from each person. There is currently no cure for Huntington's disease.

Sources:

* \*https://www.wehi.edu.au/research-diseases/development-and-ageing/neurodegenerative-disorders
* \*\* https://brainfoundation.org.au/

## Slide 6: Definitions – Disability types description (continued)

This slide is a continuation of the previous.

* Motor neurone disease:

This is a name given to a group of diseases in which the nerve cells (neurons) that control the muscles degenerate and die. Early symptoms are mild and include muscle wasting, muscle weakness, fasciculations (muscle twitching), difficulty swallowing and with speech, muscle cramps and spasms. Most cases occur spontaneously though some are hereditary (about 10%).

There are different types of Motor neurone disease and symptoms vary from person to person. Patterns of weakness, the rate and pattern of progression and survival time are also variable. There is no cure nor prevention at this time. In most cases, intellect and memory are not affected by this condition, nor are the senses of sight, hearing, taste, smell, and sensation.

* Multiple sclerosis:

This is the most common acquired chronic neurological disease affecting young adults. It is most commonly diagnosed between the ages of 20 and 40, and in Australia every three out four people diagnosed are women.

There are three forms: relapse-remitting, secondary progressive, and progressive. While there is no cure, most people with this condition live near-normal life spans. Several studies have suggested that a person lives around seven years less than people without it. Most people with the condition tend to die from the same conditions that people without it tend to die from, such as cancer and heart disease.

* Parkinson's disease:

This is a progressive, degenerative neurological condition that affects the control of body movements. It causes trembling in the hands, arms, legs, jaw, and face; rigidity or stiffness of the limbs or trunk; slowness of body movements; and unstable posture and difficulty in walking. Early symptoms are subtle and occur gradually.

Parkinson’s disease is a chronic, progressive illness, and no drug can prevent the progression of the disease.

Source: https://brainfoundation.org.au/

## Slide 7: Description – Key terms

This slide defines the key terms used in this report.

Active participant: Those who have been determined eligible, have a current approved plan and have not exited the Scheme.

Carer: Someone who provides personal care, support and assistance to a person with a disability and who is not contracted as a paid or voluntary worker.

Culturally and Linguistically Diverse (CALD): Country of birth is not Australia, New Zealand, the United Kingdom, Ireland, the United States of America, Canada, or primary language spoken at home is not English.

Outcomes framework questionnaires: One way in which the Agency is measuring success for participants and their families/carers with disability across eight different life domains.

Plan: Agreements under which reasonable and necessary supports will be funded for participants.

Participant service guarantee: A set of target timeframes for processes within the National Disability Insurance Agency relating to the participant pathway. It is part of the Participant Services Charter which explains what participants can expect when dealing with the Agency.

Participation rate: Sometimes referred to as prevalence rate, is the number of individuals in the NDIS as a proportion of the general population who have a defined level of disability at a specified point in time or over a specified period of time and have joined the Scheme.

Supported Independent Living (SIL): Supported Independent Living (SIL) is help with and/or supervision of daily tasks to develop the skills of an individual to live as independently as possible.

## Slide 8: Definitions – Key measures

This slide defines the key measures used in this report.

Average committed supports: Also referred to as plan budgets. The cost of supports contained within a participant’s plan, approved to be provided to support a participant’s needs.","This amount is annualised to allow for comparison of plans of different lengths, and averaged over the relevant NDIS population being analysed. In this report, this is based on supports allocated to active plans at 31 March 2021.

*Note: In-kind supports are provided via existing Commonwealth or State/ Territory government programs delivered under existing block grant funding arrangements. Committed supports shown in this report include most in-kind supports but do not include off-system in-kind or residential aged care reconciliations.*

Average payments: Payments are made to providers, participants or their nominees for supports received as part of a participant’s plan. In this report, average payments represent the average cash and in-kind supports paid over the reporting period based on payments data at 31 March 2021.

Average utilisation of committed supports: Utilisation represents the proportion of committed supports in participant plans that are utilised. Utilisation is calculated as total payments (including cash and in-kind, where it can be allocated to participant plans) divided by total committed supports. In this report, average utilisation of committed supports is calculated for a 6 month period, from 30 June 2020 to 31 December 2020, allowing for payment delays of up to 3 months.

Complaint rate: Complaint rates are calculated as the number of complaints made by people who have sought access divided by the number of people who have sought access. The number of people who have sought access used in the calculation takes into account the length of time since access was sought.

## Slide 9: Part 1: Participants

This slide introduces Part 1: Participants.

As at 31 March 2021, there were 449,998 active NDIS participants with an approved plan. Of these:

* 2,258 (0.5%) had Muscular dystrophy.
* 945 (0.2%) had Huntington’s disease.
* 789 (0.2%) had Motor neurone disease.
* 8,263 (1.8) had Multiple sclerosis.
* 2,134 (0.5) had Parkinson’s disease.

## Slide 10: Summary

This slide summarises the key statistics from Part 1.

This section presents information on the characteristics of NDIS participants with a neurodegenerative condition as their primary disability as at 31 March 2021.

Key statistics:

Muscular dystrophy:

* 2,470 people with Muscular dystrophy have ever been eligible to the Scheme.
* 2,423 participants with Muscular dystrophy have had an approved plan.
* 2,258 participants with Muscular dystrophy are currently active with an approved plan.
* 0.5% of participants with an approved plan across the Scheme as a whole.

Huntington’s disease:

* 1,113 people with Huntington’s disease have ever been eligible to the Scheme.
* 1,082 participants with Huntington’s disease have had an approved plan.
* 945 participants with Huntington’s disease are currently active with an approved plan.
* 0.2% of participants with an approved plan across the Scheme as a whole.

Motor neurone disease:

* 1,534 people with Motor neurone disease have ever been eligible to the Scheme.
* 1,440 participants with Motor neurone disease have had an approved plan.
* 789 participants with Motor neurone disease are currently active with an approved plan.
* 0.2% of participants with an approved plan across the Scheme as a whole.

Multiple sclerosis:

* 8,731 people with Multiple sclerosis have ever been eligible to the Scheme.
* 8,547 participants with Multiple sclerosis have had an approved plan.
* 8,263 participants with Multiple sclerosis are currently active with an approved plan.
* 1.8% of participants with an approved plan across the Scheme as a whole.

Parkinson’s disease:

* 2,402 people with Parkinson’s disease have ever been eligible to the Scheme.
* 2,296 participants with Parkinson’s disease have had an approved plan.
* 2,134 participants with Parkinson’s disease are currently active with an approved plan.
* 0.5% of participants with an approved plan across the Scheme as a whole.

The Scheme as a whole:

* 488,813 people across the Scheme as a whole have ever been eligible to the Scheme.
* 467,266 participants across the Scheme as a whole have had an approved plan.
* 449,998 participants across the Scheme as a whole are currently active with an approved plan.

## Slide 11: Participation rates by State/Territory

This slide has two (2) charts which display participation rates by State/Territory compared with national average for Muscular dystrophy and Huntington’s disease.

Participation rate refers to the proportion of the general population that are NDIS participants. For this purpose the rates are based on participants below 65 years old with the disability type being reported.

The national participation rate for participants with a neurodegenerative condition is relatively low compared to other disabilities. The participation rate is highest at 33.6 participants per 100,000 population for Multiple sclerosis, followed by 10.0 participants per 100,000 population for Muscular dystrophy, 7.3 participants per 100,000 population for Parkinson's disease, 3.9 participants per 100,000 population for Huntington's disease, and 3.2 participants per 100,000 population for Motor neurone disease.

The participation rates for Muscular dystrophy and Motor neurone disease are highest in South Australia, while for Huntington's disease, Multiple sclerosis and Parkinson's disease, the participation rates are highest in Tasmania.

## Slide 12: Participation rates by State/Territory (continued)

This slide has three (3) charts which display participation rates by State/Territory compared with national average for Motor neurone disease, Multiple sclerosis and Parkinson’s disease.

There is no commentary on this slide.

## Slide 13: Participation rates by age group

This slide has two (2) charts which display participation rates by age group compared with the national average for Muscular dystrophy and Huntington’s disease.

The rate of participation in the NDIS varies by age, and this variation differs significantly across disability types.

For participants with Muscular dystrophy, the participation rates are relatively even across the age groups, with slightly higher rates for younger participants aged below 25 years, and for participants aged 45-64 years. For participants with Huntington's disease, Motor neurone disease or Multiple sclerosis, the participation rates are very low at the younger ages, with a steep increase from around the age of 35 years. For participants with Parkinson's disease, the participation rates remain low until around 55 years of age.

Note: The participation rates are not shown for age groups with 20 or less participants.

## Slide 14: Participation rates by age group (continued)

This slide has three (3) charts which display participation rates by age group compared with the national average for Motor neurone disease, Multiple sclerosis and Parkinson’s disease.

Note: The participation rates are not shown for age groups with 20 or less participants.

There is no commentary on this slide.

## Slide 15: Participants over time

This slide has two (2) charts which display the numbers of active participants with Muscular dystrophy or Huntington’s disease and also the proportions of participants with these disability types as a percentage of the Scheme as a whole over time. The charts are plotted biannually from December 2017 to March 2021.

For those with a neurodegenerative condition except for Parkinson's disease, the number of active participants with an approved plan continues to increase at a decreasing rate compared to the Scheme as a whole. The proportions of these participants increased up to December 2018 or June 2019 and have decreased subsequently. For participants with Parkinson's disease, the number of active participants continues to increase at a higher rate than the Scheme overall, with the proportion of participants increasing steadily since December 2017.

At 31 March 2021, there were:

* 2,258 participants (0.5% of the Scheme) with Muscular dystrophy.
* 945 participants (0.2% of the Scheme) with Huntington's disease.
* 789 participants (0.2% of the Scheme) with Motor neurone disease.
* 8,263 participants (1.8% of the Scheme) with Multiple sclerosis.
* 2,134 participants (0.5% of the Scheme) with Parkinson's disease.

## Slide 16: Participants over time (continued)

This slide has three (3) charts which display the numbers of active participants with Motor neurone disease, Multiple sclerosis or Parkinson’s disease and also the proportions of participants with these disability types as a percentage of the Scheme as a whole over time. The charts are plotted biannually from December 2017 to March 2021.

There is no commentary on this slide.

## Slide 17: Participants by age group

This slide has two (2) charts which display the age distributions of active participations for Muscular dystrophy and Huntington’s disease compared with the distribution of the Scheme as a whole.

The distribution of active participants by age group is considerably older for participants with a neurodegenerative condition than the Scheme as a whole:

* 60% of active participants with Muscular dystrophy are aged 25 and over.
* 97% of active participants with Huntington's disease are aged 25 or over.
* 99% of active participants with Motor neurone disease are aged 25 or over.
* 99% of active participants with Multiple sclerosis are aged 25 or over.
* 100% of active participants with Parkinson's disease are aged 25 or over.

These compare with 43% for the Scheme overall.

Active participants with Muscular dystrophy have the highest proportion of children compared to other neurodegenerative conditions in this report. However, the age distribution for children and those below 25 are still different compared to the Scheme as a whole as 21% of active participants with Muscular dystrophy are aged 0 to 14 and a further 19% are aged 15 to 24, compared with 41% and 16% respectively across all active participants in the Scheme.

## Slide 18: Participants by age group (continued)

This slide has three (3) charts which display the age distributions of active participations for Motor neurone disease, Multiple sclerosis and Parkinson’s disease compared with the distribution of the Scheme as a whole.

Active participants with Parkinson's disease have the highest proportion of older participants compared to other neurodegenerative conditions in this report, with 86% aged 55 and over.

Note: There are no participants aged 14 or below with Parkinson’s disease.

## Slide 19: Participants by Indigenous and CALD status

This slide has two (2) charts which display the proportions of active participants with Indigenous and CALD statuses for each neurodegenerative condition, compared with the Scheme as a whole.

The proportion of active participants with a neurodegenerative condition that identify as Aboriginal and/or Torres Strait Islander is lower than the Scheme as a whole. This proportion is lowest for active participants with Multiple sclerosis at 1.3%, compared with the overall Scheme proportion of 6.8%.

The proportion of active participants that identify as Culturally and Linguistically Diverse (CALD) is generally higher for those with a neurodegenerative condition than for the Scheme as a whole (9.4%). This proportion is double for active participants with Parkinson's disease (17.6%) and below the Scheme overall for participants with Huntington's disease (6.3%).

## Slide 20: Participants by Existing/New status, by level of function

This slide has two (2) charts which display the distributions of active participants by Existing or New entry type status, as well as by level of function for each neurodegenerative condition, compared with the Scheme as a whole.

Participants with a neurodegenerative condition of Muscular dystrophy or Multiple sclerosis have higher proportions of participants who previously received existing State/Territory or Commonwealth services prior to entering the Scheme, at 62% and 53% respectively, compared with 49% for the Scheme overall.

At 31 March 2021, around half of all participants did not receive government support before joining the NDIS (New). In comparison, the proportions are:

* 38% for Muscular dystrophy
* 52% for Huntington's disease
* 71% for Motor neurone disease
* 47% for Multiple sclerosis
* 74% for Parkinson's disease.

A participant's level of function is assessed across a range of domains such as self-care, mobility and communication. Overall level of function is a broad measure to gauge high level relativities between participant cohorts.

Over half of all participants with a neurodegenerative condition, except for Multiple sclerosis, have a low level of function compared to the Scheme as a whole (27%):

* 50% for Muscular dystrophy
* 79% for Huntington's disease
* 74% for Motor neurone disease
* 34% for Multiple sclerosis
* 62% for Parkinson's disease.

## Slide 21: Participants by gender and remoteness

This slide has two (2) charts which display the distributions of active participants by gender as well as by geographical remoteness of residence for each neurodegenerative condition, compared with the Scheme as a whole.

Across the Scheme overall, 37% of participants with an approved plan identify as female and 62% identify as male. However, the distribution varies by neurodegenerative condition.

The proportion of participants with Multiple sclerosis who identify as female is the highest at 74%, followed by Huntington's disease at 52%. In contrast, the majority of the other participants with a neurodegenerative condition identify as male.

Based on geographical remoteness, active participants across all neurodegenerative conditions predominantly live in major cities. The proportions are very similar in comparison to the Scheme as a whole.

## Slide 22: Part 2: Participant experience

This slide introduces Part 2: Participant experience.

A higher proportion of individuals who present to the NDIS with a neurodegenerative condition, except Parkinson's disease, meet the access criteria relative to individuals with other disabilities.

The Agency has commenced measuring a number of metrics under the Participant Service Guarantee. Results on achieving target timeframes for those with a neurodegenerative condition are included in this section, along with comparisons with the experience of the Scheme overall.

Results for these disability types are also presented in relation to other aspects of the participant experience in the NDIS including methods of plan management, participant exits from the Scheme, and participant complaints.

## Slide 23: Summary

This slide summarises key statistics from Part 2.

This section presents information on the characteristics of NDIS participants with a neurodegenerative condition as their primary disability as at 31 March 2021.

Muscular dystrophy:

* 93% of access decisions among participants with Muscular dystrophy are 'access met'
* 100% of access decisions for those with Muscular dystrophy were made within 14 days
* 76% of initial plans were approved within 56 days for participants with Muscular dystrophy aged 7 and above
* 13% is the annualised rate of participant complaints for those with Muscular dystrophy

Huntington’s disease:

* 97% of access decisions among participants with Huntington’s disease are 'access met'
* 100% of access decisions for those with Huntington’s disease were made within 14 days
* 42% of initial plans were approved within 56 days for participants with Huntington’s disease aged 7 and above
* 10% is the annualised rate of participant complaints for those with Huntington’s disease

Motor neurone disease:

* 99% of access decisions among participants with Motor neurone disease are 'access met'
* 100% of access decisions for those with Motor neurone disease were made within 14 days
* 88% of initial plans were approved within 56 days for participants with Motor neurone disease aged 7 and above
* 13% is the annualised rate of participant complaints for those with Motor neurone disease

Multiple sclerosis:

* 87% of access decisions among participants with Multiple sclerosis are 'access met'
* 100% of access decisions for those with Multiple sclerosis were made within 14 days
* 79% of initial plans were approved within 56 days for participants with Multiple sclerosis aged 7 and above
* 12% is the annualised rate of participant complaints for those with Multiple sclerosis

Parkinson’s disease:

* 82% of access decisions among participants with Parkinson’s disease are 'access met'
* 86% of access decisions for those with Parkinson’s disease were made within 14 days
* 87% of initial plans were approved within 56 days for participants with Parkinson’s disease aged 7 and above
* 9% is the annualised rate of participant complaints for those with Parkinson’s disease

The Scheme as a whole:

* 85% of access decisions among participants across the Scheme as a whole are 'access met'
* 98% of access decisions across the Scheme as a whole were made within 14 days
* 79% of initial plans were approved within 56 days for participants across the Scheme as a whole aged 7 and above
* 5% is the annualised rate of participant complaints across the Scheme as a whole

## Slide 24: Access decisions and PSG Access metrics

This slide has one (1) chart which displays the percentages of access decisions resulting in ‘access met’ overall. In addition, key findings from PSG Access metrics are summarised although not graphed.

The proportions of access decisions resulting in 'access met' are higher for individuals with a neurodegenerative condition than the Scheme overall, with the exception of Parkinson's disease.

Participants with Motor neurone disease have the highest overall rate of 'access met' decisions at 99%, compared with 85% for the Scheme overall. The rates for participants with Huntington's disease, Muscular dystrophy and Multiple sclerosis are 97%, 93% and 87% respectively. Participants with Parkinson's disease have a lower proportion of 'access met' decisions compared to the Scheme as a whole at 82%.

The Participant Service Guarantee (PSG) is a set of target timeframes for Agency processes. It is part of the Participant Services Charter\* which explains what participants can expect when dealing with the Agency.

An access related PSG metric is making an access decision within 14 days of final information being provided. Results for this metric are not graphed here.

The Agency’s performance against this metric is positive with the target being achieved for 98% of decisions across the March 2020 to the March 2021 quarters. For participants with Muscular dystrophy, Huntington's disease and Motor neurone disease, performance has been higher than the overall Scheme performance at 100% across the last four quarters. For those with Multiple sclerosis and Parkinson's disease, the performance has been largely positive, at 96% or higher. However, the experience in the latest quarter for participants with Parkinson's disease is considerably poorer at 86%, noting that the number of decisions is relatively small.

\* More information about the Participant Services Charter and the Participant Service Guarantee can be found here: [Service charter | NDIS](https://www.ndis.gov.au/about-us/policies/service-charter)

## Slide 25: Access decisions by age group

This slide has two (2) charts which display the percentages of access decisions resulting in ‘access met’ for each age group and for Muscular dystrophy and Huntington’s disease compared with those for the Scheme as a whole.

Across all decisions made to determine access to the NDIS, the proportion of 'access met' decisions is generally higher for children and decreases steadily as age increases.

For participants with a neurodegenerative condition, the proportions of 'access met' decisions do not vary greatly by age, and are higher than the Scheme experience for all age groups, except Multiple sclerosis for ages 15 to 34 years.

Note: The proportion of ‘access met’ decisions is not shown for age groups with 20 or less people for whom an access decision has been made.

## Slide 26: Access decisions by age group (continued)

This slide has three (3) charts which display the percentages of access decisions resulting in ‘access met’ for each age group and for Motor neurone disease, Multiple sclerosis and Parkinson’s disease compared with those for the Scheme as a whole.

Note: The proportion of ‘access met’ decisions is not shown for age groups with 20 or less people for whom an access decision has been made.

There is no commentary on this slide.

## Slide 27: Participant Service Guarantee: Planning metrics

This slide has two (2) charts which display the numbers of plan approvals for participants aged 7 and over, as well as the percentage approved within 70 days (56 days for Q3 2020-21) of access decision for Muscular dystrophy and Huntington’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

Under the PSG, the Agency will target to approve an initial plan for each participant aged 7 years and over within 56 days of the access decision being made (the target changed from 70 days previously to a stricter 56 days from 1 February 2021).

The proportion of applications achieving the target timeframe has increased for the Scheme overall from 58% in the March 2020 quarter to 92% in the December 2020 quarter. The proportion has dropped to 79% in the March 2021 quarter, due to the stricter timeframe of 56 days applied\*. The trend for participants with a neurodegenerative condition follows a similar pattern.

For participants with Motor neurone disease, Multiple sclerosis and Parkinson's disease, the performance is consistently better than the Scheme overall. For participants with Muscular dystrophy and Huntington's disease, the performance is lower than the Scheme as a whole in the March 2021 quarter, although the number of plans approved are relatively low.

\*The Scheme metric for March 2021 (79%) is based on the methodology of assuming the stricter metric of 56 days over the entire quarter (for simplicity). However, if the analysis applied the more lenient 70 days target for January and the stricter 56 days for February and March, then the proportion of applications that achieved this time frame would have been 82%.

Note: Results for prior periods have been restated using data at 31 March 2021.

## Slide 28: Participant Service Guarantee: Planning metrics (continued)

This slide has three (3) charts which display the numbers of plan approvals for participants aged 7 and over, as well as the percentage approved within 70 days (56 days for Q3 2020-21) of access decision for Motor neurone disease, Multiple sclerosis and Parkinson’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

Separately, there is a PSG target to approve an initial plan for each ECEI participant aged 0 to 6 years within 90 days of the access being made. However, there are insufficient results to report on the target timeframes for participants aged 0 to 6 with a neurodegenerative condition receiving an initial plan. This is driven by the majority of participants with a neurodegenerative condition being adults. Results for this metric are not presented here.

Note: Results for prior periods have been restated using data at 31 March 2021.

## Slide 29: Participant Service Guarantee: Participant Requested Review metrics

This slide has two (2) charts which display the numbers of participant requested reviews, as well as the percentage of reviews completed within 42 days of making the decision to conduct the review for Muscular dystrophy and Huntington’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

There are two PSG metrics being measured in relation to Participant Requested Reviews (PRRs).

The first is making a decision on whether to conduct a PRR within 21 days of a request being received. This has been achieved in 100% of applications in each of the last four quarters for participants with a neurodegenerative condition, and also for the Scheme overall. Results for this metric are not presented here.

There is a further target under the PSG of completing a PRR within 42 days of making the decision to conduct the review. The Agency's performance against this target timeframe has generally improved over the year to December 2020 before decreasing to 67% in the March 2021 quarter.

Note: Results for prior periods have been restated using data at 31 March 2021.

## Slide 30: Participant Service Guarantee: Participant Requested Review metrics (continued)

This slide has three (3) charts which display the numbers of participant requested reviews, as well as the percentage of reviews completed within 42 days of making the decision to conduct the review for Motor neurone disease, Multiple sclerosis and Parkinson’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

The performance for participants with a neurodegenerative condition mirrors the Scheme experience relatively closely for the December 2020 and prior quarters. For the March 2021 quarter, the proportions meeting the target timeframe are higher than the Scheme overall for participants with Motor neurone disease and Multiple sclerosis at 100% and 73% respectively, and lower for participants with Muscular dystrophy, Huntington's disease and Parkinson's disease at 63%, 59% and 55% respectively.

Note: Results for prior periods have been restated using data at 31 March 2021.

## Slide 31: Participant Service Guarantee: Review of Reviewable Decision metrics

This slide has two (2) charts which display the numbers of reviews of reviewable decisions, as well as the percentage of reviews completed within 90 days of the request being received for Muscular dystrophy and Huntington’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

A Review of a Reviewable Decision (RoRD) is an internal review of a decision the Agency has made about a participant under Section 100 of the NDIS Act. Under the PSG, the Agency will aim to complete a RoRD within 90 days of the request to conduct the review being received.

The performance of the Agency in achieving this target timeframe has improved for the overall Scheme since March 2020, but has deteriorated after 31 December 2020 to 91% in the most recent quarter. For participants with a neurodegenerative condition, the performance has been consistently better than the Scheme overall since March 2020, increasing to 100% or close to 100% in the March 2021 quarter. Note however, the number of reviewable decisions in the latest quarter is low for each of the conditions.

Note: Results for prior periods have been restated using data at 31 March 2021.

## Slide 32: Participant Service Guarantee: Review of Reviewable Decision metrics (continued)

This slide has three (3) charts which display the numbers of reviews of reviewable decisions, as well as the percentage of reviews completed within 90 days of the request being received for Motor neurone disease, Multiple sclerosis and Parkinson’s disease compared with the Scheme as a whole. The charts are plotted quarterly from March 2020 to March 2021.

Note: Results for prior periods have been restated using data at 31 March 2021.

There is no commentary on this slide.

## Slide 33: Participants by plan management type

This slide has two (2) charts which display the distributions of participants across four different plan management types, namely agency-managed, plan-managed, self-managed partly and self-managed fully, for Muscular dystrophy and Huntington’s disease. The charts are plotted biannually from December 2017 to March 2021.

There is a continuing trend for more participants to self-manage their plans or use a plan management provider, and for less participants to have their plan Agency-managed. This is the case for participants with a neurodegenerative condition and for the Scheme overall.

At 31 March 2021, a higher proportion of participants with a neurodegenerative condition used a plan manager compared to 47% for the Scheme overall, at 69% for Huntington's disease and Motor neurone disease, 63% for Parkinson's disease, 55% for Multiple sclerosis and 51% for Muscular dystrophy.

The proportion of participants who fully or partly self-managed their plans were lower than the Scheme average of 31% for participants with Huntington's disease (10%), Motor neurone disease (27%) and Parkinson's disease (27%), and higher for those with Muscular dystrophy (36%) and Multiple sclerosis (35%).

## Slide 34: Participants by plan management type (continued)

This slide has three (3) charts which display the distributions of participants across four different plan management types, namely agency-managed, plan-managed, self-managed partly and self-managed fully, for Motor neurone disease, Multiple sclerosis and Parkinson’s disease. The charts are plotted biannually from December 2017 to March 2021.

There is no commentary on this slide.

## Slide 35: Plan duration

This slide has one (1) chart which displays the distribution of plan duration in active plans for each neurodegenerative condition, compared to the Scheme as a whole.

For participants across the Scheme as a whole, around three quarters (75%) have plans with a one-year duration. This proportion is similar or slightly higher for participants with Muscular dystrophy (75%), Huntington's disease (78%), Multiple sclerosis (77%), and Parkinson's disease (80%). On the contrary, only 57% of participants with Motor neurone disease have plans with a one-year duration, with a high proportion (38%) having plans with a duration of less than 12 months (mostly 6-9 months). This likely reflects the rapidly progressing nature of the condition and the complexity of each individual case involved. A shorter plan would allow a more frequent review of the changing needs of the participant over time.

## Slide 36: Assistive technology and support coordination in plans

This slide has two (2) charts which display the percentage of active participants who have assistive technology or support coordination in their plans, for each neurodegenerative condition, compared to the Scheme as a whole.

Participants with a neurodegenerative condition are more likely to have assistive technology and support coordination in their plan.

Assistive technology is in 22% of active plans across the Scheme overall, while for participants with a neurodegenerative condition, this proportion is three to four times higher, at 96% for participants with Motor neurone disease, 80% for those with Muscular dystrophy, 76% for those with Huntington's disease, 71% for those with Multiple sclerosis, and 67% for those with Parkinson's disease.

Support coordination is in 42% of active plans across the Scheme overall, while for participants with a neurodegenerative condition, this proportion is higher at 56% and above. The proportion is particularly high for participants with Huntington's disease and Motor neurone disease at 97%. This is consistent with NDIA practice guidelines of including coordination of supports for participants requiring intensive and frequent support in progressing through the NDIS pathway.

## Slide 37: Scheme exit rates over time

This slide has two (2) charts which display exit rates by financial year for Muscular dystrophy and Huntington’s disease broken down into mortality and non-mortality exits, as well as a comparison with the Scheme as a whole.

The rates at which NDIS participants exit the Scheme vary over time and are also impacted by other factors including disability type. Exit rates due to mortality are monitored separately to those for other reasons such as participant initiated withdrawal or no longer requiring supports.

Participants with Motor neurone disease, Huntington's disease and Parkinson's disease have much higher exit rates compared with the Scheme overall, as do those with Muscular dystrophy since 2018-19. However, participants with Multiple sclerosis have lower exit rates. Across the five disability types, there is a much greater proportion of mortality exits compared to non-mortality exits.

## Slide 38: Scheme exit rates over time (continued)

This slide has three (3) charts which display exit rates by financial year for Motor neurone disease, Multiple sclerosis and Parkinson’s disease broken down into mortality and non-mortality exits, as well as a comparison with the Scheme as a whole.

There is no commentary on this slide.

## Slide 39: Complaint rates

This slide has two (2) charts which display the numbers of complaints and complaint rates for Muscular dystrophy and Huntington’s disease, compared with the Scheme’s average complaint rates over time. The charts are plotted quarterly from September 2016 to March 2021.

For each of the five disability types, the annualised rate of complaints (measured as the number of complaints as a proportion of access requests) is high compared with the Scheme overall.

The rates of complaints have declined over the past year for all participants with a neurodegenerative condition, except for Huntington's disease where the rate has increased slightly. However, in March 2021, the rates of complaints were still relatively high for participants with a neurodegenerative condition, at 13% for participants with Muscular dystrophy and Motor neurone disease, 12% for Multiple sclerosis, 10% for Huntington's disease and 9% for Parkinson's disease, compared with the overall Scheme experience of 5%.

The Agency aims to resolve complaints within 21 days of receiving them. Since December 2019, the proportion of complaints where this target was achieved has improved significantly for the Scheme as a whole, from 58% in the December 2019 quarter to 91% in the March 2021 quarter. Results for participants with a neurodegenerative condition are in line with the Scheme overall, noting there is a degree of volatility due to low numbers.

## Slide 40: Complaint rates (continued)

This slide has three (3) charts which display the numbers of complaints and complaint rates for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme’s average complaint rates over time. The charts are plotted quarterly from September 2016 to March 2021.

There is no commentary on this slide.

## Slide 41: Part 3: Committed supports, payments and utilisation

This slide introduces Part 3: Committed supports, payments and utilisation.

Committed supports and payments to participants with a neurodegenerative condition are increasing in line with the growing Scheme.

The total committed supports for the 2020-21 financial year to date (1 July 2020 - 31 March 2021) were:

* $211m for participants with Muscular dystrophy
* $150m for participants with Huntington's disease
* $149m for participants with Motor neurone disease
* $660m for participants with Multiple sclerosis, and
* $176m for participants with Parkinson's disease.

Among the five neurodegenerative conditions, the rate of utilisation of committed supports is highest for participants with Muscular dystrophy at 67%, and lowest for those with Motor neurone disease at 57%.

These compare to the Scheme average of 68%.

## Slide 42: Summary

This slide summarises key statistics from Part 3.

This section presents information on the amounts of supports committed in participant plans for participants with a neurodegenerative condition as their primary disability. Utilisation rates, which are the proportion of committed supports actually used, are also presented.

Participants with Muscular dystrophy:

* $230 million of supports in respect of 2019-20 financial year
* $211 million of supports in respect of 2020-21 financial year to date
* 67% of supports utilised

Participants with Huntington’s disease:

* $148 million of supports in respect of 2019-20 financial year
* $150 million of supports in respect of 2020-21 financial year to date
* 65% of supports utilised

Participants with Motor neurone disease:

* $157 million of supports in respect of 2019-20 financial year
* $149 million of supports in respect of 2020-21 financial year to date
* 57% of supports utilised

Participants with Multiple sclerosis:

* $699 million of supports in respect of 2019-20 financial year
* $660 million of supports in respect of 2020-21 financial year to date
* 64% of supports utilised

Participants with Parkinson’s disease:

* $158 million of supports in respect of 2019-20 financial year
* $176 million of supports in respect of 2020-21 financial year to date
* 61% of supports utilised

The Scheme as a whole:

* $24.572 million of supports in respect of 2019-20 financial year
* $23,615 million of supports in respect of 2020-21 financial year to date
* 68% of supports utilised

## Slide 43: Trend in committed supports

This slide has two (2) charts which display the trend in average annualised committed supports in thousands of dollars for Muscular dystrophy and Huntington’s disease, compared with the Scheme’s average committed supports. The charts are plotted biannually from December 2017 to March 2021.

Participants with a neurodegenerative condition have significantly higher average annualised committed supports compared with the Scheme overall. In particular, participants with Motor neurone disease have the highest average annualised committed supports, followed by Huntington's disease.

At 31 March 2021, the average annualised committed supports were:

* $242,000 for participants with Motor neurone disease
* $212,000 for participants with Huntington's disease
* $123,000 for participants with Muscular dystrophy
* $116,000 for participants with Parkinson's disease, and
* $108,000 for participants with Multiple sclerosis.

These compare to the average annualised committed supports of $70,000 across the Scheme.

Average annualised committed supports have increased over time. The rate of increase for participants with a neurodegenerative condition is higher than for the Scheme as a whole, and is the highest for participants with Huntington's disease.

## Slide 44: Trend in committed supports (continued)

This slide has three (3) charts which display the trend in average annualised committed supports in thousands of dollars Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme’s average committed supports. The charts are plotted biannually from December 2017 to March 2021.

There is no commentary on this slide.

## Slide 45: Committed supports by age group

This slide has two (2) charts which display the average annualised committed supports in thousands of dollars for different age groups and for Muscular dystrophy and Huntington’s disease, compared with the Scheme’s average committed supports for these age groups.

The average annualised committed supports for participants with Muscular dystrophy, Huntington's disease and Motor neurone disease are higher than Scheme average at each age group, and are significantly higher in the case of Huntington's disease and Motor neurone disease. For participants with Multiple sclerosis and Parkinson's disease, the average annualised committed supports are closer to Scheme average.

The average annualised committed supports for participants with Muscular dystrophy are highest at ages 25 to 34. For those with Huntington's disease and Motor neurone disease, amounts are highest at ages 15 to 54 and ages 35 to 54 respectively. Participants with Multiple sclerosis and Parkinson's disease have high average amounts in ages 45 and up.

Notes: Total\* in the charts refers to the average annualised committed supports based on the age distribution of all Scheme participants. This has an effect of reducing the average for each of the five disability types.

The average annualised committed supports are not shown for age groups with 20 or less participants.

## Slide 46: Committed supports by age group (continued)

This slide has three (3) charts which display the average annualised committed supports in thousands of dollars for different age groups and for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme’s average committed supports for these age groups.

Notes: Total\* in the charts refers to the average annualised committed supports based on the age distribution of all Scheme participants. This has an effect of reducing the average for each of the five disability types.

The average annualised committed supports are not shown for age groups with 20 or less participants.

There is no commentary on this graph.

## Slide 47: Committed supports by SIL status

This slide has two (2) charts which display the average annualised committed supports for participants in SIL and non-SIL arrangements respectively. Each chart compares committed supports for each neurodegenerative disability with the Scheme’s average committed supports, as well as indicating the percentage of participants in SIL and non-SIL arrangements, respectively.

Participants with Supported Independent Living (SIL) tend to have much higher committed supports than those without SIL. This is the case for participants across the Scheme and within each neurodegenerative condition.

For participants with SIL, the average annualised committed supports for all conditions are higher than the average across the Scheme, notably Huntington's disease with the highest average annualised committed supports for participants with SIL at $512,000 compared with $347,000 for the Scheme as a whole.

Among the five conditions, it is worth noting that 14% of participants with Huntington's disease have SIL supports which is high compared with 6% for the Scheme overall. The proportion for the rest of the conditions are lower than All Scheme, at around 2-3%.

The average annualised committed supports for participants without SIL are also higher than for the Scheme as a whole, and are highest for those with Motor neurone disease at $238,000, followed by Huntington's disease at $163,000, compared with the Scheme average of $54,000.

Note: Since June 2020 there has been an issue with identifying SIL in plans as they are being completed. For these results, the numbers of SIL participants include an estimate of participants who should be identified as having SIL in their plans but do not appear as such on the Agency’s system at 31 March 2021.

## Slide 48: Distribution of committed supports

This slide has two (2) charts which display the distributions of annualised committed supports per participant across various cost bands for Muscular dystrophy and Huntington’s disease, compared with the Scheme as a whole.

Compared with the Scheme overall, the distribution of annualised committed supports is more concentrated at the higher cost bands for participants with a neurodegenerative condition.

Around one quarter of participants with Muscular dystrophy, Multiple sclerosis, or Parkinson's disease have between $50,000 and $100,000 of annualised committed supports.

For participants with Motor neurone disease, 33% have annualised committed supports greater than $250,000, compared with just 6% for the Scheme overall. The proportion of participants in this group is also high for Huntington's disease at 24%.

## Slide 49: Distribution of committed supports (continued)

This slide has three (3) charts which display the distributions of annualised committed supports per participant across various cost bands for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme as a whole.

There is no commentary on this slide.

## Slide 50: Types of committed supports

This slide has two (2) charts which display the total annualised committed supports and percentage allocation of committed supports by support type for Muscular dystrophy and Huntington’s disease.

Majority of committed supports in participant plans are for Core supports and over half of all supports are for Core daily activities for all the neurodegenerative conditions. This category makes up 64% of all committed supports for participants with Huntington's disease, 58% of all committed supports for those with Motor neurone disease, 52% of all committed supports for those with Muscular dystrophy and Multiple sclerosis, and 53% of supports for those with Parkinson's disease. The overall Scheme average is lower at 46%.

The second largest category is Core community participation, at up to 20% of all committed supports for participants with a neurodegenerative condition. Capital is a relatively significant component for Muscular dystrophy, Motor neurone disease and Multiple sclerosis, at 11-13%.

## Slide 51: Types of committed supports (continued)

This slide has three (3) charts which display the total annualised committed supports and percentage allocation of committed supports by support type for Motor neurone disease, Multiple sclerosis and Parkinson’s disease.

There is no commentary on this slide.

## Slide 52: Changes in committed supports

This slide has two (2) charts which display the distributions of changes in annualised plan costs for participants with Muscular dystrophy or Huntington’s disease, compared with overall Scheme experience.

The proportion of participants who have had a change of less than 5% in their annualised plan value compared with their previous plan is lower for each of the five conditions compared to the overall Scheme experience. The proportion is lowest for Muscular dystrophy at 18%, compared to the Scheme experience of 26%.

On the other hand, the proportion of participants who have had increases in their annualised plan value is higher for each of the five conditions compared to the overall Scheme experience. Notably, the proportion of participants with an increase of more than 50% in their annualised plan value is 20% for Muscular dystrophy, and 18% for Huntington's disease and Motor neurone disease, compared to 16% for the Scheme overall. This reflects the degenerative nature of the conditions, with the support needs of participants increasing over time.

## Slide 53: Changes in committed supports (continued)

This slide has three (3) charts which display the distributions of changes in annualised plan costs for participants with Motor neurone disease, Multiple sclerosis or Parkinson’s disease, compared with overall Scheme experience.

There is no commentary on this slide.

## Slide 54: Average annualised payments

This slide has two (2) charts which display the average annualised payments over time for Muscular dystrophy and Huntington’s disease, compared with the Scheme’s average annualised payments. The charts are plotted annually from financial year 2017-18 to financial year 2020-21 to date. The per annum average annual rate of increase for each disability type is also quoted on each chart.

Average annualised payments for participants' supports are significantly higher for participants with a neurodegenerative condition than for the Scheme as a whole. This is consistent with the high levels of committed supports for these participants.

For 2020-21 to date, the average annualised payments for participants with Huntington's disease and Motor neurone disease were remarkably high at around $153,000 compared with the average of $52,800 across the Scheme as a whole. For Muscular dystrophy, Multiple sclerosis, and Parkinson's disease, the amounts were $87,000, $74,200, and $78,000 respectively.

These disability types have seen large increases in payments in each year since 2017-18, with average annual increases of 25% to 49%, compared with the overall Scheme average of 11%.

## Slide 55: Average annualised payments (continued)

This slide has three (3) charts which display the average annualised payments over time for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme’s average annualised payments. The charts are plotted annually from financial year 2017-18 to financial year 2020-21 to date. The per annum average annual rate of increase for each disability type is also quoted on each chart.

There is no commentary on this slide.

## Slide 56: Utilisation by time in the Scheme

This slide has two (2) charts which display the utilisation rates of committed supports by date of first plan approval for Muscular dystrophy and Huntington’s disease, compared with utilisation rates across the Scheme. Each bar in the series represents a participant cohort who had their first plan approved within the specified period. In addition, a bar on the left indicates the average utilisation rates over time.

Utilisation rates in this report are based on committed supports for the period 1 July 2020 to 31 December 2020 and including all payments made as at 31 March 2021. This is to allow for lags in payments as experience in the most recent months is still emerging.

The rate of utilisation of committed supports for participants with a neurodegenerative condition is lower than the Scheme average of 68%. The rate of utilisation is lowest for participants with Motor neurone disease at 57%, followed by participants with Parkinson's disease at 61%. Among the five conditions, the rate of utilisation is highest for participants with Muscular dystrophy at 67%.

A possible reason for the lower rates of utilisation experienced by participants with a neurodegenerative condition is that in creating an NDIS plan, consideration is given to the progressive nature of neurodegenerative conditions so as to include supports designed to meet the rapidly changing needs of participants, which may not be initially utilised.

Duration in the Scheme is a key driver of utilisation. Participants utilise a greater proportion of committed supports as their time in the Scheme increases. This is evident for each disability type.

## Slide 57: Utilisation by time in the Scheme (continued)

This slide has three (3) charts which display the utilisation rates of committed supports by date of first plan approval for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with utilisation rates across the Scheme. Each bar in the series represents a participant cohort who had their first plan approved within the specified period. In addition, a bar on the left indicates the average utilisation rates over time.

There is no commentary on this slide.

## Slide 58: Utilisation by age group

This slide has two (2) charts which display the utilisation rates of committed supports by age group for Muscular dystrophy and Huntington’s disease, compared with the Scheme’s average utilisation rates. In addition, a bar is added on the left to indicate average utilisation rate for all age groups.

Utilisation by age group is presented based on active participants only, who have been in the Scheme for at least one year. This is to remove the impact of new entrants to the Scheme who tend to have low utilisation.

For all conditions, utilisation of committed supports is lower than Scheme average in all age groups, except participants with Huntington's disease aged 25 to 44 years where utilisation of supports is higher than Scheme average. The differences in utilisation are generally greater for older participants compared to younger participants.

Note: The utilisation of committed supports are not shown for age groups with 20 or less participants.

## Slide 59: Utilisation by age group (continued)

This slide has three (3) charts which display the utilisation rates of committed supports by age group for Motor neurone disease, Multiple sclerosis and Parkinson’s disease, compared with the Scheme’s average utilisation rates. In addition, a bar is added on the left to indicate average utilisation rate for all age groups.

Note: The utilisation of committed supports are not shown for age groups with 20 or less participants.

There is no commentary on this slide.

## Slide 60: Utilisation by SIL status

This slide has two (2) charts which display the utilisation rates for participants in SIL and non-SIL arrangements respectively, and each chart compares utilisation rates of each neurodegenerative condition with the Scheme’s average utilisation rates.

Utilisation of committed supports for participants under Supported Independent Living (SIL) arrangements is consistently higher than for participants without SIL. This is the case across the Scheme and within each neurodegenerative condition.

For participants with SIL, utilisation rates for all conditions are slightly lower than the Scheme average of 85%.

For participants without SIL, the utilisation rate for those with Muscular dystrophy is at 65%, which is higher than the Scheme average of 62%. For the remaining conditions, the utilisation rates are lower than the Scheme average, with participants with Huntington's disease having the lowest utilisation at 55%.

Note: Since June 2020 there has been an issue with identifying SIL in plans as they are being completed. For these results, the numbers of SIL participants include an estimate of participants who should be identified as having SIL in their plans but do not appear as such on the Agency’s system at 31 March 2021.

## Slide 61: Part 4: Participant goals, outcomes and satisfaction

This slide introduces Part 4: Participant goals, outcomes and satisfaction.

Participants set goals as part of the planning process. Participants with a neurodegenerative condition most often set goals related to daily life, social and community activities, and health and wellbeing.

Information on participant and family and carers outcomes is collected at entry to the Scheme and at subsequent plan reviews. Outcomes for participants with a neurodegenerative condition have improved across most indicators.

A participant satisfaction survey is conducted to gauge the level of satisfaction with Agency processes. It shows that the majority of participants with a neurodegenerative condition rate the Agency's performance as 'good' or 'very good'.

## Slide 62: Participant goals, outcomes and satisfaction - technical notes

This slide outlines the technicalities in this section relating to simplifying assumptions on participant characteristics, average time in the Scheme and participant level of function.

1. When comparing the indicators for participants with a neurodegenerative condition with the Scheme as a whole, consider the following:
* In addition to a primary disability group, other participant characteristics (such as age, gender, level of function) can influence experiences and outcomes of a participant and their family and carers. These other factors were not adjusted for in any of the calculations.
* In the "Longitudinal outcomes" section, we report participant and family and carers outcomes at baseline and the latest review, thereby gaining insights into the changes over the period since participants entered the Scheme. Due to phasing and general variability of factors leading to Scheme entry, the average time in the Scheme can be different for participants with a neurodegenerative condition compared to the Scheme as a whole. However, after carrying out analysis, the differences in the average durations were not found to have a material effect on the outcomes.
* In the "Has the NDIS Helped" section, we compare the latest satisfaction rates for participants with a neurodegenerative condition and the Scheme overall. Since the average time in the Scheme for participants with a neurodegenerative condition can be different to the Scheme as a whole, the comparison can be affected by the differences. Similar to the “Longitudinal outcomes” section, based on the analysis, we found that the differences in duration did not have a material effect on the "Has the NDIS Helped?" indicators.
* B) Participant level of function has been found to be positively correlated with better outcomes at baseline and longitudinally. For participants with a neurodegenerative condition, level of function tends to decrease over time, and to a greater extent compared to the Scheme as a whole. The differences in level of function between baseline and latest review were significantly different to the rest of the Scheme for participants aged 25 and over with the following disabilities: Motor neurone disease, Parkinson's disease, Muscular dystrophy, and Huntington's disease. Less favourable longitudinal outcomes for these participants compared to the overall Scheme can be partially attributed to decreasing level of function.

More information on the association between participant level of function and outcomes can be found in Participant outcomes reports (www.data.ndis.gov.au/reports-and-analyses/outcomes-and-goals/participant-outcomes-report).

## Slide 63: Summary

This slide summarises key statistics from Part 4.

This section presents information on goals, satisfaction, as well as outcomes for participants with a primary neurodegenerative condition and their families and carers across various life domains.

Outcomes are measured when participants enter the Scheme to obtain baseline indicators, as well as at subsequent reviews to monitor longitudinal changes and gauge participant satisfaction via "Has the NDIS Helped?" questions.

Participant satisfaction with the Agency's services is collected using a survey, asking participants to give a rating for each of the four main stages of the participant pathway: access, pre-planning, planning, and plan review.

Muscular dystrophy:

* % of participants who choose who supports them at baseline: 82%
* % of participants rating their health as excellent, very good or good at baseline: 31%
* Change in the % of participants who participate in social and community activities: +9%
* Change in the % of participants who are in a paid job: -3%
* % of participants who said that the NDIS helped them have more choices and control in their life: 84%
* % of participants who said that the NDIS improved their health and wellbeing: 63%

Huntington’s disease:

* % of participants who choose who supports them at baseline: 54%
* % of participants rating their health as excellent, very good or good at baseline: 27%
* Change in the % of participants who participate in social and community activities: +6%
* Change in the % of participants who are in a paid job: +0%
* % of participants who said that the NDIS helped them have more choices and control in their life: 77%
* % of participants who said that the NDIS improved their health and wellbeing: 58%

Motor neurone disease:

* % of participants who choose who supports them at baseline: 87%
* % of participants rating their health as excellent, very good or good at baseline: 23%
* Change in the % of participants who participate in social and community activities: +7%
* Change in the % of participants who are in a paid job: -8%
* % of participants who said that the NDIS helped them have more choices and control in their life: 87%
* % of participants who said that the NDIS improved their health and wellbeing: 69%

Multiple sclerosis:

* % of participants who choose who supports them at baseline: 85%
* % of participants rating their health as excellent, very good or good at baseline: 27%
* Change in the % of participants who participate in social and community activities: +5%
* Change in the % of participants who are in a paid job: -2%
* % of participants who said that the NDIS helped them have more choices and control in their life: 83%
* % of participants who said that the NDIS improved their health and wellbeing: 66%

Parkinson’s disease:

* % of participants who choose who supports them at baseline: 77%
* % of participants rating their health as excellent, very good or good at baseline: 20%
* Change in the % of participants who participate in social and community activities: +6%
* Change in the % of participants who are in a paid job: -3%
* % of participants who said that the NDIS helped them have more choices and control in their life: 84%
* % of participants who said that the NDIS improved their health and wellbeing: 67%

The Scheme as a whole:

* % of participants who choose who supports them at baseline: 60%
* % of participants rating their health as excellent, very good or good at baseline: 42%
* Change in the % of participants who participate in social and community activities: +9%
* Change in the % of participants who are in a paid job: -2%
* % of participants who said that the NDIS helped them have more choices and control in their life: 77%
* % of participants who said that the NDIS improved their health and wellbeing: 58%

## Slide 64: Key findings

This slide summarises key findings from Part 4, outlining key points from participant outcomes, family/carer outcomes, participant goals and Participant Satisfaction Survey, respectively.

Participant outcomes:

* At Scheme entry, participants with a neurodegenerative condition tend to have more favourable outcomes than the Scheme average in the areas of advocacy, choosing who supports them, and deciding what to do each day. However, they have less favourable outcomes related to self-rated health.
* Community participation among participants with a neurodegenerative condition improved during their time in the Scheme.
* The percentage in paid employment for participants aged 25 and over with Huntington's disease, Motor neurone disease, and Parkinson's disease was lower at baseline compared to the overall Scheme. And, since Scheme entry, the percentages declined further.
* Participants with a neurodegenerative condition are more likely to say the NDIS helped improve their outcomes in choice and control as well as daily living. However, they are less likely to say the NDIS helped with lifelong learning and employment.

Family/carer outcomes:

* The percentage of families and carers of participants with a neurodegenerative condition in paid employment is generally higher compared to the Scheme overall at baseline.
* Longitudinal changes for families and carers of participants with a neurodegenerative conditions are generally in line with the Scheme.

Participant goals:

* Participants with a neurodegenerative condition are more likely to set goals related to health and wellbeing compared to the rest of Scheme.

Participant satisfaction:

* Participant satisfaction rates with planning and review processes are generally in line with the Scheme overall.

## Slide 65: Participant goals

This slide has three (3) charts which display the percentage of active participants who have set one or more goals within each outcomes domain for Muscular dystrophy, Huntington’s disease and Motor neurone disease, compared with the Scheme as a whole.

As part of the planning process, participants set goals about what they would like to achieve across various domains. These goals tend to vary by disability type.

For participants with Muscular dystrophy:

They are the most likely of all neurodegenerative conditions to set goals on daily life (84%). However, they are relatively less likely than other neurodegenerative conditions to set goals on health and wellbeing (57%) or where they live (26%), albeit still considerably more likely than the Scheme averages of 38% and 18% respectively.

For participants with Huntington's disease:

Results for this disability type are more varied. They are the most likely of all neurodegenerative conditions to set goals on social and community activities (81%), relationships (27%), as well as where they live (52%, almost triple that of the Scheme average). However, they are the least likely to have goals on daily life (71%) and employment (just 4%, well below the the Scheme average of 19%).

For participants with Motor neurone disease:

While being the most likely of all neurodegenerative conditions to have goals about choice and control over their lives (30%), they are among the least likely (5%, far below the Scheme average of 25%) to set learning-related goals. They are also just 3% less likely than the Scheme as a whole to set relationship goals, one of the highest among all neurodegenerative conditions.

## Slide 66: Participant goals (continued)

This slide has two (2) charts which display the percentage of active participants who have set one or more goals within each outcomes domain for Multiple sclerosis and Parkinson’s disease, compared with the Scheme as a whole.

For participants with Multiple sclerosis:

They are 29% more likely than the Scheme average to set health and wellbeing goals, as well as being 1% more likely than the Scheme average to set employment goals, the only neurodegenerative condition where the rate of employment goals is higher than the Scheme average. However, they are the least likely (66%, just 6% above the Scheme average) to have goals for social and community activities.

For participants with Parkinson's disease:

Just 15% of participants with Parkinson's disease have set goals with respect to relationships, compared to 29% for the Scheme as a whole. On the other hand, they are more likely to set goals with respect to social and community participation, with 72% of them doing so compared to the Scheme average of 60%.

Overall with respect to individual participant goal domains, participants with a neurodegenerative condition, relative to the Scheme as a whole:

* are slightly more likely to set goals regarding choice and control;
* are almost equally likely to set goals to do with daily life;
* are substantially more likely to set goals regarding health and wellbeing;
* are substantially less likely to set goals with regards to learning;
* are slightly less likely to set goals regarding relationships;
* are slightly more likely to set goals on social and community activities;
* are slightly more likely to set goals to do with where they live;
* are slightly less likely to set goals related to employment.

## Slide 67: Participant baseline outcomes – Muscular dystrophy

This slide has one (1) chart which displays selected baseline outcomes indicators for participants with Muscular dystrophy aged 0 to 14, 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % who feel able to advocate (stand up) for themselves
* % who rate their health as excellent, very good or good
* % who choose who supports them
* % who have friends other than family or paid staff
* % who choose what they do each day
* % who are happy with the home they live in
* % who are currently working in a paid job
* % who have been actively involved in a community, cultural or religious group in the last 12 months

This information on participant baseline indicators has been collected from participants with Muscular dystrophy who received their initial plan since 1 July 2016 (when they entered the Scheme).

Baseline outcomes for participants with Muscular dystrophy relative to the Scheme overall vary by domain.

At Scheme entry, participants with Muscular dystrophy on average fare better in self-advocacy, friendships, choosing who supports them, and choosing what they do each day. However, the percentage of participants who rate their health as good, very good or excellent is lower compared to the Scheme average. The outcomes related to employment, community participation and housing are similar to the Scheme average.

## Slide 68: Participant baseline outcomes – Huntington’s disease

This slide has one (1) chart which displays selected baseline outcomes indicators for participants with Huntington’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % who feel able to advocate (stand up) for themselves
* % who rate their health as excellent, very good or good
* % who choose who supports them
* % who have friends other than family or paid staff
* % who choose what they do each day
* % who are happy with the home they live in
* % who are currently working in a paid job
* % who have been actively involved in a community, cultural or religious group in the last 12 months

This information on participant baseline indicators has been collected from participants with Huntington's disease who received their initial plan since 1 July 2016 (when they entered the Scheme).

For participants with Huntington's disease, outcomes for the eight indicators shown are generally less positive than for the Scheme as a whole.

In particular, only 27% of participants with Huntington's disease rate their own health positively, compared to 42% of the Scheme as a whole. Although 22% of participants aged 25 and over across the Scheme are working in a paid job, this is true for only 2% of those with Huntington's disease.

## Slide 69: Participant baseline outcomes – Motor neurone disease

This slide has one (1) chart which displays selected baseline outcomes indicators for participants with Motor neurone disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % who feel able to advocate (stand up) for themselves
* % who rate their health as excellent, very good or good
* % who choose who supports them
* % who have friends other than family or paid staff
* % who choose what they do each day
* % who are happy with the home they live in
* % who are currently working in a paid job
* % who have been actively involved in a community, cultural or religious group in the last 12 months

This information on participant baseline indicators has been collected from participants with Motor neurone disease who received their initial plan since 1 July 2016 (when they entered the Scheme).

For participants with Motor neurone disease, outcomes in most domains differ substantially from the Scheme overall. Exceptions are working in a paid job and being actively involved in a community, cultural or religious group, featuring differences of -2% and +3% compared to the Scheme average, respectively.

Participants with Motor neurone disease are 28% more likely than the Scheme average to be able to advocate for themselves, 27% more likely to choose who supports them, 19% more likely to have friends other than family or paid staff and 20% more likely to choose what they do each day. On the other hand, their outcomes are worse than the Scheme as a whole in self-rated health and being happy with the home they live in.

## Slide 70: Participant baseline outcomes – Multiple sclerosis

This slide has one (1) chart which displays selected baseline outcomes indicators for participants with Multiple sclerosis aged 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % who feel able to advocate (stand up) for themselves
* % who rate their health as excellent, very good or good
* % who choose who supports them
* % who have friends other than family or paid staff
* % who choose what they do each day
* % who are happy with the home they live in
* % who are currently working in a paid job
* % who have been actively involved in a community, cultural or religious group in the last 12 months

This information on participant baseline indicators has been collected from participants with Multiple sclerosis who received their initial plan since 1 July 2016 (when they entered the Scheme).

For participants with Multiple sclerosis, outcomes are more favourable than the Scheme as a whole across most indicators, and the difference is more pronounced for the 15 to 24 age group. However, self-rated health is lower than the Scheme overall, and differences are smaller for home.

Highlights in outcomes of participants with Multiple sclerosis include:

* Paid employment rate of 44% for those aged 15 to 24, notably higher than the Scheme average of 18%;
* 65% of those aged 15 to 24 are able to advocate for themselves compared to just 28% for the Scheme overall;
* 78% of those aged 15 to 24 choose who supports them compared to just 37% for the Scheme overall.

## Slide 71: Participant baseline outcomes – Parkinson’s disease

This slide has one (1) chart which displays selected baseline outcomes indicators for participants with Parkinson’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % who feel able to advocate (stand up) for themselves
* % who rate their health as excellent, very good or good
* % who choose who supports them
* % who have friends other than family or paid staff
* % who choose what they do each day
* % who are happy with the home they live in
* % who are currently working in a paid job
* % who have been actively involved in a community, cultural or religious group in the last 12 months

This information on participant baseline indicators has been collected from participants with Parkinson's disease who received their initial plan since 1 July 2016 (when they entered the Scheme).

For participants with Parkinson's disease, outcomes relative to the Scheme average are similar to those with Motor neurone disease for most domains. Their outcomes are higher than the Scheme average in being able to advocate for themselves, choosing who supports them, making friends beyond family and paid staff and choosing what they do each day. On the other hand, they are less than half as likely to rate their health positively, (20% compared to 42% for the Scheme overall). They are also 8% less likely to be working in a paid job compared to the Scheme as a whole.

## Slide 72: Family/carer baseline outcomes – Muscular dystrophy

This slide has one (1) chart which displays selected baseline outcomes indicators for families and carers of participants with Muscular dystrophy aged 0 to 14, 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in paid job
* % working as much as they want while providing informal care
* % advocating (standing up) for their family member with disability
* % rate their health as "Excellent", "Very Good" or "Good"
* % having friends they can see as often as they'd like
* % receiving Carer Payment
* % receiving Carer Allowance
* % feeling in control selecting the services

This information on baseline indicators has been collected from families/carers of participants with Muscular dystrophy where the participant entered the Scheme since 1 July 2016.

The results for participants with Muscular dystrophy are close to the Scheme average across most domains, with the following exceptions:

* The percentage of families and carers receiving Carer Payment and Carer Allowance for participants with Muscular dystrophy are higher than the Scheme as a whole;
* The percentages who are able to work as much as they want while providing informal carer is lower than the Scheme as a whole;
* The percentage of families and carers of participants with Muscular dystrophy aged 0 to 14 who rated their health as "Excellent", "Very Good" or "Good" is 67%, 8% lower than 75% for the Scheme as a whole. This gap narrowed for families and carers of participants aged 15 and over.

\* Data for Carer Payment and Carer Allowance receipt are based on self-reported information.

## Slide 73: Family/carer baseline outcomes – Huntington’s disease

This slide has one (1) chart which displays selected baseline outcomes indicators for families and carers of participants with Huntington’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in paid job
* % working as much as they want while providing informal care
* % advocating (standing up) for their family member with disability
* % rate their health as "Excellent", "Very Good" or "Good"
* % having friends they can see as often as they'd like
* % receiving Carer Payment
* % receiving Carer Allowance
* % feeling in control selecting the services

This information on baseline indicators has been collected from families/carers of participants with Huntington's disease where the participant entered the Scheme since 1 July 2016.

The results for families or carers of participants with Huntington's disease are:

* Similar to the Scheme average for being able to advocate for the participant, as well as Carer Payment and Carer Allowance;
* Lower than overall Scheme results when it comes to being able to work as much as wanted, having friends to see as often as wanted, and feeling in control in selecting services and supports for the participant;
* Higher than the Scheme as a whole for paid employment rate (14% higher) and positive self-rated health.

## Slide 74: Family/carer baseline outcomes – Motor neurone disease

This slide has one (1) chart which displays selected baseline outcomes indicators for families and carers of participants with Motor neurone disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in paid job
* % working as much as they want while providing informal care
* % advocating (standing up) for their family member with disability
* % rate their health as "Excellent", "Very Good" or "Good"
* % having friends they can see as often as they'd like
* % receiving Carer Payment
* % receiving Carer Allowance
* % feeling in control selecting the services

This information on baseline indicators has been collected from families/carers of participants with Motor neurone disease where the participant entered the Scheme since 1 July 2016.

The results for families or carers of participants with Motor neurone disease can be summarised as follows:

* 65% are able to advocate for the participant and 39% feel in control selecting services and supports for the participants, both proportions are very close to the Scheme average;
* Over 10% more likely than the Scheme as a whole to be in paid employment and to rate their health positively;
* However, when it comes to being able to work as much as they want while providing informal care, only 42% responded positively, compared to 56% for the Scheme as a whole.

## Slide 75: Family/carer baseline outcomes – Multiple sclerosis

This slide has one (1) chart which displays selected baseline outcomes indicators for families and carers of participants with Multiple sclerosis aged 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in paid job
* % working as much as they want while providing informal care
* % advocating (standing up) for their family member with disability
* % rate their health as "Excellent", "Very Good" or "Good"
* % having friends they can see as often as they'd like
* % receiving Carer Payment
* % receiving Carer Allowance
* % feeling in control selecting the services

This information on baseline indicators has been collected from families/carers of participants with Multiple sclerosis where the participant entered the Scheme since 1 July 2016.

The results for families or carers of participants with Multiple sclerosis relative to the Scheme vary by domain and by participant age group. They are more likely than the Scheme average to be in a paid job, advocate for the participant and self-rate health positively. However, they are less likely to be able to work as much as wanted compared to the Scheme overall.

Families and carers of participants aged 15 to 24 are less likely than the Scheme average to receive Carer Payment and Carer Allowances, and more likely to have friends to see as often as they like. These conclusions are the opposite for families and carers of participants aged 25 and over, namely, being more likely than the Scheme average to receive Carer Payment and Carer Allowance, as well as being less likely to have friends they see as often as they like.

## Slide 76: Family/carer baseline outcomes – Parkinson’s disease

This slide has one (1) chart which displays selected baseline outcomes indicators for families and carers of participants with Parkinson’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in paid job
* % working as much as they want while providing informal care
* % advocating (standing up) for their family member with disability
* % rate their health as "Excellent", "Very Good" or "Good"
* % having friends they can see as often as they'd like
* % receiving Carer Payment
* % receiving Carer Allowance
* % feeling in control selecting the services

This information on baseline indicators has been collected from families/carers of participants with Parkinson's disease where the participant entered the Scheme since 1 July 2016.

The results for families or carers of participants with Parkinson's disease have shown less deviation from the Scheme average compared to other disability types discussed above, with all of them being within 8% of the Scheme average. The largest deviations are for paid employment rate (8% higher than Scheme overall), being able to work as much as they want (6% lower than Scheme overall) and being able to advocate for the participant (6% higher than Scheme overall).

On the other hand, 33% reported that they are receiving Carer Allowance and 38% feel in control selecting services and supports for the participant, both of which are almost identical percentages compared to the Scheme as a whole.

## Slide 77: Participant longitudinal outcomes – Muscular dystrophy

This slide has two (2) charts which display selected longitudinal outcomes indicators for participants with Muscular dystrophy aged 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* Participant social and community participation
* Participant rating their health as "Excellent", "Very Good" or "Good"
* Participant choosing who supports them
* Participant in paid employment

Longitudinal outcomes in this section serve the following purposes:

* Outcomes are graphed for participants at Scheme entry (baseline) as well as their latest review to show longitudinal changes over time.
* Trends in indicators for participants with a neurodegenerative condition are contrasted with the Scheme as a whole.
* These results are based on participants who have been in the Scheme for at least two years, measured at baseline and at their latest plan review.

Outcomes in social and community participation for participants with Muscular dystrophy aged 15 and over improved over time, similar to the Scheme overall.

However, the percentage rating their health positively decreased by 6%, more than the Scheme as a whole (a decrease of 3%).

Participants with Muscular dystrophy aged 15 to 24 were more likely than the Scheme average to choose who supports them at baseline, 43% compared to 31% for the Scheme overall. This difference widened to 15 percentage points at latest review.

Compared to the Scheme overall, participants with Muscular dystrophy aged 15 to 24 were less likely to work in a paid job, however, the percentage in paid employment improved over time in the Scheme, from 6% to 11%. Participants aged 25 and over have similar employment outcomes to the Scheme average at both baseline and latest review.

## Slide 78: Participant longitudinal outcomes – Huntington’s disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for participants with Huntington’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* Participant social and community participation
* Participant rating their health as "Excellent", "Very Good" or "Good"
* Participant choosing who supports them
* Participant in paid employment

Compared with the Scheme as a whole, participants with Huntington's disease were more likely to experience a decline in the outcome related to self-rated health. The percentage of participants who rate their health as good, very good or excellent decreased from 30% at baseline to 22% at latest review, compared to 49% and 46% for the Scheme as a whole.

The percentage of participants choosing who supports them decreased since baseline by 6 percentage points, from 51% to 45%. At the same time, this indicator remained stable for the Scheme as whole, at 53% at baseline and 54% at latest review.

The outcome for social and community participation improved, from 26% at baseline to 32% at latest review, albeit to a lesser extent than the Scheme average (37% at baseline and 46% at latest review).

The percentage of participants with Huntington's disease in paid employment remained at a lower level compared to the Scheme overall.

## Slide 79: Participant longitudinal outcomes – Motor neurone disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for participants with Motor neurone disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* Participant social and community participation
* Participant rating their health as "Excellent", "Very Good" or "Good"
* Participant choosing who supports them
* Participant in paid employment

Outcomes in social and community participation for participants with Motor neurone disease improved by 7 percentage points from baseline to latest review, slightly lower compared to 9 percentage points for the Scheme average.

In relation to employment, the percentage of participants with Motor neurone disease with a paid job has decreased considerably, from 16% at baseline to 8% at latest review. The result for the Scheme as whole is less unfavourable, a 2 percentage points decrease.

Similarly, the indicator for self-rated health of participants with Motor neurone disease deteriorated by 8 percentage points, from 28% at baseline to 20% at latest review, a worse outcome compared to a decrease of 3 percentage points for the Scheme as a whole.

## Slide 80: Participant longitudinal outcomes – Multiple sclerosis

This slide has one (1) chart which displays selected longitudinal outcomes indicators for participants with Multiple sclerosis aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* Participant social and community participation
* Participant rating their health as "Excellent", "Very Good" or "Good"
* Participant choosing who supports them
* Participant in paid employment

The percentage of participants with Multiple sclerosis participating in social and community activities improved by 5% from baseline to latest review, which is a smaller increase compared to the Scheme overall (+9%).

With regards to self-rated health, the percentage of participants with Multiple sclerosis who rated their health positively has decreased by 6 percentage points, from 29% at baseline to 23% at latest review. This is a larger deterioration compared to the Scheme as a whole (-3%).

The percentage of participants in a paid employment decreased by 2 percentage points both for participants with Multiple sclerosis and the Scheme as a whole.

## Slide 81: Participant longitudinal outcomes – Parkinson’s disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for participants with Parkinson’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* Participant social and community participation
* Participant rating their health as "Excellent", "Very Good" or "Good"
* Participant choosing who supports them
* Participant in paid employment

The percentage of participants with Parkinson's disease who positively rated their health decreased by 9 percentage points, compared to a decrease of only 3 percentage points for the Scheme average.

Outcomes in social and community participation improved (+6%), albeit at a slower rate than the Scheme as a whole (+9%).

The percentage choosing who supports them also increased slightly, similar to the Scheme overall.

## Slide 82: Family/Carer longitudinal outcomes – Muscular dystrophy

This slide has two (2) charts which display selected longitudinal outcomes indicators for families and carers of participants with Muscular dystrophy aged 15 to 24 as well as 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in a paid job
* % feeling in control selecting supports

Longitudinal outcomes in this section serve the following purposes:

* Outcomes are graphed for families and carers of participants at Scheme entry (baseline) as well as their latest review to show longitudinal changes over time.
* Trends in indicators for families and carers of participants with a neurodegenerative condition are contrasted with the Scheme as a whole.
* These results are based on families/carers of participants who have been in the Scheme for at least two years, measured at baseline and at their latest plan review.

In terms of employment, the percentage of families and carers of participants with Muscular dystrophy who have a paid job declined slightly for the "age 15 to 24" group and increased for the "age 25 and over" group.

As for feeling in control when selecting services, the indicator for families and carers of participants with Muscular dystrophy aged 15 to 24 declined by 4 percentage points (from 30% to 26%), while it improved for the Scheme as a whole (an increase of 3 percentage points from 40% to 43%). For those aged 25 and over, family/carers of participants reported an improvement of 3 percentage points (from 39% to 42%), while the Scheme average remained constant at 42%.

## Slide 83: Family/Carer longitudinal outcomes – Huntington’s disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for families and carers of participants with Huntington’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in a paid job
* % feeling in control selecting supports

Employment outcomes based on the selected indicator remained stable for families and carers of participants with Huntington's disease, compared to a decrease of 2 percentage points for the Scheme as a whole.

As for feeling in control selecting supports, the percentage for families and carers with Huntington's disease decreased by 3 percentage points while the Scheme as a whole remained constant.

## Slide 84: Family/Carer longitudinal outcomes – Motor neurone disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for families and carers of participants with Motor neurone disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in a paid job
* % feeling in control selecting supports

The percentage of families and carers of participants with Motor neurone disease in a paid job decreased substantially by 16 percentage points, from 62% at baseline to 46% at latest review. In contrast, this indicator decreased by just 2 percentage points, from 36% to 34%, for the Scheme as a whole.

More families and carers of participants with Motor neurone disease feel in control selecting supports compared to baseline (44% and 50% at latest review), a more favourable outcome compared to the Scheme average (constant at 42%).

## Slide 85: Family/Carer longitudinal outcomes – Multiple sclerosis

This slide has one (1) chart which displays selected longitudinal outcomes indicators for families and carers of participants with Multiple sclerosis aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in a paid job
* % feeling in control selecting supports

The percentage of families and carers of participants with Multiple sclerosis in paid employment decreased by 1 percentage point since baseline, while the Scheme as a whole decreased by 2 percentage points.

Families and carers of participants with Multiple sclerosis on average felt more in control selecting services and supports, with the percentage increasing from 41% at baseline to 46% at latest review, in contrast with the Scheme overall which showed almost no change.

## Slide 86: Family/Carer longitudinal outcomes – Parkinson’s disease

This slide has one (1) chart which displays selected longitudinal outcomes indicators for families and carers of participants with Parkinson’s disease aged 25 and over, compared with the Scheme as a whole. The graphed outcomes indicators are:

* % in a paid job
* % feeling in control selecting supports

The percentage of families and carers of participants with Parkinson's disease in a paid job decreased by 4 percentage points from 39% at baseline to 35% at latest review, similar to the Scheme as a whole (a 2 percentage-point decrease, from 36% to 34%).

The percentage feeling in control selecting services improved by 3 percentage points from 47% at baseline to 50% at latest review, while the Scheme average remained constant at 42%.

## Slide 87: Has the NDIS Helped participants – Muscular dystrophy (participants from starting school to age 14)

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for participants with Muscular dystrophy aged 0 to 14, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped your child to become more independent?
* Has the NDIS improved your child's access to education?
* Has the NDIS improved your child's relationships with family and friends?
* Has the NDIS improved your child's social and recreational life?

Participants are asked whether the NDIS has helped them at each plan review across various domains. These charts summarise the responses for participants who have been in the Scheme for at least two years and compare the average satisfaction rates at first review (R1) with those at the latest review.

For the starting school to age 14 group, participants with Muscular dystrophy rated the NDIS less favourably than the Scheme average in helping them improve outcomes, across all domains. This is true for both first and latest review.

In particular, 48% of NDIS participants from starting school to age 14 at first review said that the NDIS improved their relationships with family and friends, compared to just 36% of those with Muscular dystrophy. However, this 12% gap narrowed to 7% at the latest review.

## Slide 88: Has the NDIS Helped participants – Muscular dystrophy (participants aged 15 and over)

This slide has two (2) charts which display the perceptions of whether the NDIS has helped improve outcomes for participants with Muscular dystrophy aged 15 to 24 as well as 25 and over, both compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped you have more choices and more control over your life?
* Has the NDIS helped you with daily living activities?
* Has the NDIS helped you to meet more people?
* Has your involvement with the NDIS helped you to choose a home that's right for you?
* Has your involvement with the NDIS improved your health and wellbeing?
* Has your involvement with the NDIS helped you to learn things you want to learn or to take courses you want to take?
* Has your involvement with the NDIS helped you find a job that's right for you?
* Has the NDIS helped you be more involved?

By contrast with the starting school to age 14 group, the percentage saying the NDIS helped has exceeded the Scheme average in some domains among participants aged 15 and over.

67% of participants with Muscular dystrophy aged 15 to 24 said that the NDIS helped them with daily living activities, compared to the Scheme average of 59%. This 8% difference increased to 10% at the latest review.

For choice and control, 70% of participants with Muscular dystrophy aged 25 and over said the NDIS helped, slightly higher than the Scheme average of 67%. At the latest review, these percentages increased considerably to 84% and 77%, representing a 7% difference from the Scheme average.

However, participants with Muscular dystrophy in both age groups are 5% to 8% less likely than participants overall to think that the NDIS has helped in the domains of lifelong learning and employment.

## Slide 89: Has the NDIS Helped participants – Huntington’s disease

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for participants with Huntington’s disease aged 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped you have more choices and more control over your life?
* Has the NDIS helped you with daily living activities?
* Has the NDIS helped you to meet more people?
* Has your involvement with the NDIS helped you to choose a home that's right for you?
* Has your involvement with the NDIS improved your health and wellbeing?
* Has your involvement with the NDIS helped you to learn things you want to learn or to take courses you want to take?
* Has your involvement with the NDIS helped you find a job that's right for you?
* Has the NDIS helped you be more involved?

Whether the NDIS has helped among participants with Huntington's disease relative to the Scheme as a whole varies substantially by domain.

In daily living, health and wellbeing, as well as social and community participation, the percentage of participants with Huntington's disease saying the NDIS helped are within 2% of the Scheme average at both first review and latest review.

Participants with Huntington's disease are 2% and 6% more likely than the Scheme average to say the NDIS helped them choose the right home at first and latest review, respectively.

However, the percentages responding positively are notably lower than the Scheme average, in lifelong learning and employment. This may reflect the low percentage of participants setting goals in these domains (see Participant Goals section).

## Slide 90: Has the NDIS Helped participants – Motor neurone disease

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for participants with Motor neurone disease aged 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped you have more choices and more control over your life?
* Has the NDIS helped you with daily living activities?
* Has the NDIS helped you to meet more people?
* Has your involvement with the NDIS helped you to choose a home that's right for you?
* Has your involvement with the NDIS improved your health and wellbeing?
* Has your involvement with the NDIS helped you to learn things you want to learn or to take courses you want to take?
* Has your involvement with the NDIS helped you find a job that's right for you?
* Has the NDIS helped you be more involved?

Participants with Motor neurone disease are more likely than the Scheme average at both first and latest review in five domains to say the NDIS helped. Less improvement is seen in participants with Motor neurone disease relative to the Scheme overall.

In choice and control as well as daily living, percentages thinking the NDIS has helped for participants with Motor neurone disease exceed the Scheme average by 10% or more.

Nevertheless, similar to Huntington's disease, participants with Motor neurone disease remained remarkably below the Scheme average in the domains of lifelong learning and employment.

Despite being 2% above the Scheme average at first review in terms of meeting more people, participants with Motor neurone disease were 6% below the Scheme average at latest review (55% compared to 61%).

## Slide 91: Has the NDIS Helped participants – Multiple sclerosis

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for participants with Multiple sclerosis aged 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped you have more choices and more control over your life?
* Has the NDIS helped you with daily living activities?
* Has the NDIS helped you to meet more people?
* Has your involvement with the NDIS helped you to choose a home that's right for you?
* Has your involvement with the NDIS improved your health and wellbeing?
* Has your involvement with the NDIS helped you to learn things you want to learn or to take courses you want to take?
* Has your involvement with the NDIS helped you find a job that's right for you?
* Has the NDIS helped you be more involved?

In three out of eight domains, participants with Multiple sclerosis were more likely to say the NDIS helped than the Scheme overall at both first and latest reviews. The opposite is true for the other five domains.

In the domains of choice and control, daily living, and health and wellbeing, participants with Multiple sclerosis consistently remained above the Scheme average by 5% to 8%.

By contrast, in regards to meeting more people and lifelong learning, participants with Multiple sclerosis were at least 10% less likely to think the NDIS has helped than the Scheme as a whole.

## Slide 92: Has the NDIS Helped participants – Parkinson’s disease

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for participants with Parkinson’s disease aged 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS helped you have more choices and more control over your life?
* Has the NDIS helped you with daily living activities?
* Has the NDIS helped you to meet more people?
* Has your involvement with the NDIS helped you to choose a home that's right for you?
* Has your involvement with the NDIS improved your health and wellbeing?
* Has your involvement with the NDIS helped you to learn things you want to learn or to take courses you want to take?
* Has your involvement with the NDIS helped you find a job that's right for you?
* Has the NDIS helped you be more involved?

Opinions on whether the NDIS helped among participants with Parkinson's disease follow a similar trend as other neurodegenerative conditions, relative to the Scheme overall. Namely, exceeding the Scheme average in daily living, but falling short in lifelong learning and finding a suitable job.

For participants with Parkinson's disease, changes in the percentage saying the NDIS helped from first to latest review closely track the Scheme average. The exception is health and wellbeing, where participants with Parkinson's disease improved by 12% over time, greater than the 9% improvement for the Scheme as a whole.

## Slide 93: Has the NDIS Helped families/carers - Muscular dystrophy (families and carers of participants aged 0 to 14)

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for families and carers of participants with muscular dystrophy aged 0 to 14, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS improved your capacity to advocate?
* Has the NDIS improved the level of support for your family?
* Has the NDIS improved your access to services, programs and activities in the community?
* Has the NDIS improved your ability/capacity to help your child develop and learn?
* Has the NDIS improved your health and wellbeing?

Families and carers of participants are asked whether the NDIS has helped them at each plan review across various domains. These charts summarise the responses for participants who have been in the Scheme for at least two years and compare the average satisfaction rates at first review (R1) with those at the latest review.

For families and carers of those aged 0 to 14, results have been mostly below the Scheme average at both first and latest review except for access to services at first review.

ln all domains except access to services, the percentage of families and carers of participants with Muscular dystrophy responding positively improved at a higher rate than the Scheme as a whole.

For access to services, the proportion of families and carers of participants with Muscular dystrophy saying the NDIS helped deteriorated while the Scheme overall improved.

## Slide 94: Has the NDIS Helped families/carers - Muscular dystrophy (families and carers of participants aged 15 and over)

This slide has two (2) charts which display the perceptions of whether the NDIS has helped improve outcomes for families and carers of participants with Muscular dystrophy aged 15 to 24 as well as 25 and over, both compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS improved your capacity to advocate?
* Has the NDIS improved the level of support for your family?
* Has the NDIS improved your access to services, programs and activities in the community?
* Has the NDIS improved your health and wellbeing?

For families and carers of participants with Muscular dystrophy aged 15 and over, the proportion saying the NDIS helped tend to improve to a greater extent than the Scheme as a whole. For the age group 15 to 24, in particular, positive response rates are below the Scheme as a whole but catch up with or even surpass the Scheme average at the latest review.

In the domain of access to services, just 38% of families and carers of participants with Muscular dystrophy aged 15 to 24 said the NDIS helped them in this regard, 19% lower than the Scheme as a whole. However, they improved by 30% over time and exceeded the Scheme average, which improved by 10%.

For families and carers of participants aged 25 and over, the greatest improvements are in the domains of level of support for family and access to services, by 19% and 20% respectively.

## Slide 95: Has the NDIS Helped families/carers – Multiple sclerosis

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for families and carers of participants with Multiple sclerosis 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS improved your capacity to advocate?
* Has the NDIS improved the level of support for your family?
* Has the NDIS improved your access to services, programs and activities in the community?
* Has the NDIS improved your health and wellbeing?

Compared to other neurodegenerative conditions, families and carers of participants with Multiple sclerosis are similar to the Scheme as a whole in the likelihood of saying the NDIS helped, especially for the domains of rights and advocacy, families feeling supported as well as health and wellbeing.

At first review, 52% of Multiple sclerosis families and carers said that the NDIS improved their access to services, programs and activities in the community, 8% lower than the 60% for the Scheme as a whole. However, the difference narrowed to 3% by the latest review (69% for Multiple sclerosis and 72% for the Scheme as a whole).

## Slide 96: Has the NDIS Helped families/carers – Parkinson’s disease

This slide has one (1) chart which displays the perceptions of whether the NDIS has helped improve outcomes for families and carers of participants with Parkinson’s disease 25 and over, compared with the Scheme as a whole. Results shown are at the first plan review and at the latest review for participants who have been in the Scheme for at least two years. The graphed outcomes indicators are:

* Has the NDIS improved your capacity to advocate?
* Has the NDIS improved the level of support for your family?
* Has the NDIS improved your access to services, programs and activities in the community?
* Has the NDIS improved your health and wellbeing?

The percentage of families and carers for participants with Parkinson's disease saying the NDIS helped are higher than the Scheme as a whole in most cases. They are more likely than the Scheme as a whole to say that the NDIS improved their outcomes in rights and advocacy, level of support for family, as well as access to services.

Improvement is lower in most domains for participants with Parkinson’s disease as compared to the Scheme average. However, there was a 13% improvement in saying the NDIS improved their health and wellbeing from first review to latest (36% to 49%), as compared to a 7% improvement for the Scheme as a whole (37% to 44%).

## Slide 97: Participant Satisfaction - the Planning stage

This slide has five (5) pie charts which display the proportions of participants by satisfaction rating for the services they received at the Planning stage of NDIS participant pathway. The results for each neurodegenerative condition are compared with the Scheme as a whole. Ratings are grouped in the following manner:

* Very Good or Good;
* Neutral;
* Poor or Very Poor.

A new participant satisfaction survey was implemented from September 2018 to better record the experience of NDIS participants and their families and carers at different stages of the participant pathway.

The survey gathers responses at four primary stages of the participant pathway: Access, Pre-planning, Planning and Plan Review.

Since October 2020, the survey has been administered by an independent third party. This has resulted in a 'break' in the time series, meaning the previous quarterly results do not compare well with those for prior quarters.

Hence, participant satisfaction results are shown for the December 2020 and March 2021 quarters only.

At the Access and Pre-planning stages, there is insufficient data for these disability types to show results separately. Results are only shown for the Planning and Plan Review pathway stages.

At the planning stage, 85% of participants in the Scheme as a whole were satisfied with their experience with the NDIA and rated the experience as "Very Good" or "Good". 9% rated their experience as neutral and 7% were dissatisfied with their experience. By comparison, among participants with a degenerative condition:

* The satisfaction rates for participants with Muscular dystrophy, Multiple sclerosis and Parkinson's disease are similar with the average Scheme ratings
* Those with Motor neurone disease are more likely to be satisfied than the Scheme average.
* The number of responses for Huntington's disease are too small to be reported.

## Slide 98: Participant Satisfaction - the Review stage

This slide has five (5) pie charts which display the proportions of participants by satisfaction rating for the services they received at the Review stage of NDIS participant pathway. The results for each neurodegenerative condition are compared with the Scheme as a whole. Ratings are grouped in the following manner:

* Very Good or Good;
* Neutral;
* Poor or Very Poor.

At the Plan Review stage, 75% of Scheme participants are satisfied with their experience with the NDIA, 13% felt neutral and 12% were dissatisfied. By comparison:

* Participants with Muscular dystrophy have similar satisfaction rates compared to the Scheme overall, albeit slightly less likely to be satisfied.
* Participants with Huntington's disease, Motor neurone disease, Multiple sclerosis or Parkinson's disease are more likely than the Scheme average to say their experience was "Very Good" or "Good". Participants with Huntington's disease or Motor neurone disease, in particular, rated the review process at least 10% higher than the Scheme as a whole.